UBS Maintains Neutral Rating on InMode, Lowers Price Target to $16.00

UBS analyst Danielle Antalffy has lowered the price target for InMode (INMD) to $16.00 from $16.25, a 1.54% decrease. Despite the lower target, the analyst maintains a Neutral rating. Investors are advised to consider the revised price target and current rating when making decisions regarding INMD shares. The company provides minimally and non-invasive surgical aesthetic and medical treatment solutions in the United States.